A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer

被引:48
作者
Rodriguez, Cristina P. [1 ]
Adelstein, David J. [1 ]
Rice, Thomas W. [2 ]
Rybicki, Lisa A. [3 ]
Videtic, Gregory M. M. [4 ]
Saxton, Jerrold P. [4 ]
Murthy, Sudish C. [2 ]
Mason, David P. [2 ]
Ives, Denise I. [1 ]
机构
[1] Cleveland Clin, Dept Solid Tumor Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dept Cardiothorac Surg, Inst Heart & Vasc, Cleveland, OH 44106 USA
[3] Cleveland Clin, Dept Quantitat Hlth Sci, Taussig Canc Inst, Cleveland, OH 44106 USA
[4] Cleveland Clin, Dept Radiat Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
关键词
Esophageal cancer; Gastroesophageal cancer; Multimodality therapy; EGFR inhibition; CELL LUNG-CANCER; POSITRON-EMISSION-TOMOGRAPHY; GROWTH-FACTOR RECEPTOR; SQUAMOUS-CELL; PREOPERATIVE CHEMORADIATION; PLUS CETUXIMAB; NECK-CANCER; TRIAL; CARCINOMA; SURGERY;
D O I
10.1097/JTO.0b013e3181c5e334
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Concurrent chemoradiotherapy (CCRT) for locoregionally advanced esophageal or gastroesophageal junction cancer produces high locoregional control rates but Suboptimal distant metastatic control (DMC) and overall Survival. This phase 11 study added gefitinib (G) to our previously tested CCRT regimen in an effort to improve these outcomes. Methods: Eligibility required T3, NI, or M1a esophageal or gastroesophageal junction squamous cell or adenocarcinoma staged by esophageal ultrasound and positron emission tomography/computed tomography. Four-day continuous intravenous infusions of cisplatin (20 mg/m(2)/d) and fluorouracil (1000 mg/m(2)/d) began on day I of preoperative radiation (30 Gy and 1.5 Gy bid). Surgery followed in 4 to 6 weeks, and an identical course of CCRT 6 to 10 weeks postoperatively. G 250 mg/d was given with preoperative CCRT for 4 weeks and restarted with postoperative therapy for 2 years. Results were retrospectively compared with our historical series of 93 patients given CCRT without G. Results: Between April 2003 and July 2006, 80 patients were enrolled. Patient and tumor characteristics were similar to our historical series. G did not increase toxicity except for development of rash in 42 (53%) and diarrhea in 44 (55%) 3-year Kaplan-Meier estimates (G versus non-G treated patients) included: Overall Survival (42% versus 28%, p = 0.06), DMC (40% versus 32%, p = 0.33), and locoregional control (76% Versus 77%, p = 0.74). Intolerance for G maintenance occurred in 48% of patients. Patients who experienced G related diarrhea appeared to have improved outcomes. Conclusions: Although G did not worsen CCRT toxicity, maintenance therapy proved difficult. This contemporary cohort of patients enjoyed superior survival, which does not solely reflect a decrease in DMC and merits further investigation.
引用
收藏
页码:229 / 235
页数:7
相关论文
共 38 条
[1]   A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction - The impact of clinical heterogeneity [J].
Adelstein, David J. ;
Rice, Thomas W. ;
Rybicki, Lisa A. ;
Saxton, Jerrold P. ;
Videtic, Gregory M. M. ;
Murthy, Sudish C. ;
Zuccaro, Gregory ;
Vargo, John J. ;
Dumot, John A. ;
Carroll, Marjorie A. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (02) :172-180
[2]  
Adelstein DJ, 1997, CANCER-AM CANCER SOC, V80, P1011
[3]  
ADELSTEIN DJ, 2005, J CLIN ONCOL ASC S16, V23
[4]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[5]   Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial [J].
Burmeister, BH ;
Smithers, BM ;
Gebski, V ;
Fitzgerald, L ;
Simes, RJ ;
Devitt, P ;
Ackland, S ;
Gotley, DC ;
Joseph, D ;
Millar, J ;
North, J ;
Walpole, ET ;
Denham, JW .
LANCET ONCOLOGY, 2005, 6 (09) :659-668
[6]  
Chen C, 2007, J CLIN ONCOL, V25, P4880, DOI 10.1200/JCO.2007.12.9650
[7]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[8]   Pharmacogenetics of ABCG2 and adverse reactions to gefitinib [J].
Cusatis, George ;
Gregorc, Vanesa ;
Li, Jing ;
Spreafico, Anna ;
Ingersoll, Roxann G. ;
Verweij, Jaap ;
Ludovini, Vienna ;
Villa, Eugenio ;
Hidalgo, Manuel ;
Sparreboom, Alex ;
Baker, Sharyn D. .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (23) :1739-1742
[9]   Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 [J].
Dragovich, Tomislav ;
McCoy, Sheryl ;
Fenoglio-Preiser, Cecilia M. ;
Wang, Jiang ;
Benedetti, Jacqueline K. ;
Baker, Amanda F. ;
Hackett, Christopher B. ;
Urba, Susan G. ;
Zaner, Ken S. ;
Blanke, Charles D. ;
Abbruzzese, James L. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4922-4927
[10]   A phase II study of gefitinib monotherapy in advanced Esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response [J].
Ferry, David R. ;
Anderson, Mark ;
Beddard, Kate ;
Tomlinson, Simon ;
Atherfold, Paul ;
Obszynska, Jolanta ;
Harrison, Rebecca ;
Jankowski, Janusz .
CLINICAL CANCER RESEARCH, 2007, 13 (19) :5869-5875